<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03127774</url>
  </required_header>
  <id_info>
    <org_study_id>AAAQ9194</org_study_id>
    <nct_id>NCT03127774</nct_id>
  </id_info>
  <brief_title>Surgery and Heated Intraperitoneal Chemotherapy for Adrenocortical Carcinoma</brief_title>
  <official_title>Phase II Trial of Surgical Resection and Heated Intraperitoneal Peritoneal Chemotherapy (HIPEC) for Adrenocortical Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Columbia University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Columbia University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Objectives:&#xD;
&#xD;
      - To determine intraperitoneal (IP) progression free survival after optimal debulking and&#xD;
      heated intraperitoneal chemotherapy (HIPEC) with cisplatin in patients with IP spread of&#xD;
      adrenocortical cancer.&#xD;
&#xD;
      - Determine morbidity of this procedure in this patient population.&#xD;
&#xD;
      - Determine the impact of surgery and HIPEC on quality of life (QOL) and hormone excess.&#xD;
&#xD;
      - Examine patterns of recurrence (local versus systemic).&#xD;
&#xD;
      - Determine overall survival after optimal debulking and HIPEC in patients with IP spread of&#xD;
      adrenocortical cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Adrenocortical carcinoma (ACC) is a rare tumor with an overall 5-year mortality rate of 75 -&#xD;
      90% and an average survival from the time of diagnosis of 14.5 months. The treatment of&#xD;
      choice for a localized primary or recurrent tumor is surgical resection of all visible tumor&#xD;
      and involved organs. For unresectable metastatic or recurrent disease, mitotane,&#xD;
      aminoglutethimide, metapyrone, and ketoconazole are used. This would be the standard of care&#xD;
      alternative treatment.&#xD;
&#xD;
      Cisplatin is one of the most effective chemotherapeutic agents for ACC. Phase I and II trials&#xD;
      using heated intraperitoneal (IP) chemotherapy with cisplatin have been conducted in other&#xD;
      tumors that spread primarily to the peritoneal lining of the abdomen. Synergy has been&#xD;
      demonstrated for cisplatin and hyperthermia. The purpose of this trial is to determine if an&#xD;
      surgical approach with intraperitoneal administration of heated cisplatin when tumor volume&#xD;
      is minimal, can impact and improve on progression free survival.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 22, 2017</start_date>
  <completion_date type="Anticipated">May 2023</completion_date>
  <primary_completion_date type="Anticipated">May 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Patients who are successfully debulked will undergo heated intraperitoneal chemotherapy with cisplatin.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression Free Survival</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>The length of time after optimal debulking and heated intraperitoneal chemotherapy that a patient lives before there is clinical evidence of recurrent adrenocortical cancer.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Morbidity Rate</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>The frequency of post-operative complications.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life (QOL) Score</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>This measures the impact of surgery and HIPEC on quality of life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>The length of time people are alive after surgery and HIPEC for adrenocortical cancer.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Adrenocortical Carcinoma</condition>
  <condition>Peritoneal Carcinomatosis</condition>
  <arm_group>
    <arm_group_label>Surgery with HIPEC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cytoreductive surgery followed by HIPEC with cisplatin and sodium thiosulfate</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>Route of administration: Intraperitoneal for tumor treatment. Dose of 250 mg/m2&#xD;
Drug 1 of the hyperthermic intraperitoneal chemotherapy (HIPEC)</description>
    <arm_group_label>Surgery with HIPEC</arm_group_label>
    <other_name>Platinol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sodium thiosulfate</intervention_name>
    <description>Route of administration: Intravenous Loading dose of 7.5 gm/m2 over 20 minutes followed by 2.13 gm/m2/hr for 12 hours&#xD;
Drug 2 given intravenously during hyperthermic intraperitoneal chemotherapy (HIPEC)</description>
    <arm_group_label>Surgery with HIPEC</arm_group_label>
    <other_name>Sodium thiosulfate injection</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Cytoreductive surgery</intervention_name>
    <description>Standard of care: Surgical procedure used to remove tumors from patients with peritoneal tumors.</description>
    <arm_group_label>Surgery with HIPEC</arm_group_label>
    <other_name>Cytoreductive debulking surgery</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        INCLUSION CRITERIA&#xD;
&#xD;
          -  Histologically proven ACC with the majority of disease confined to the peritoneal&#xD;
             cavity and resectable or amenable to radiofrequency ablation&#xD;
&#xD;
          -  Disease evaluable by CT or Positron Emission Tomography (PET) imaging&#xD;
&#xD;
          -  All disease should be deemed resectable based on imaging studies e.g.:&#xD;
&#xD;
               -  Hepatic metastases (unilateral or bilateral less than or equal to 5 lesions, less&#xD;
                  than or equal to 15 cm total diameter)&#xD;
&#xD;
               -  Note: Hepatic lesions must be amenable to complete resection&#xD;
&#xD;
               -  Primary peritoneal metastases (small disease load less than or equal to P2&#xD;
                  disease) without massive ascites or intestinal obstruction&#xD;
&#xD;
               -  Lung metastases (less than or equal to 3 unilateral/bilateral, 9 cm total&#xD;
                  diameter)&#xD;
&#xD;
               -  Note: lung lesions must be amenable to complete resection&#xD;
&#xD;
               -  Note: Patients with both pulmonary and hepatic metastases will be enrolled at the&#xD;
                  discretion of the PI&#xD;
&#xD;
               -  Note: In situations where resection to Completeness of Cytoreduction Score (CC) 0&#xD;
                  or 1 is uncertain, patients may undergo diagnostic laparoscopy prior to&#xD;
                  enrollment to determine feasibility of resection.&#xD;
&#xD;
          -  Greater than or equal to 18 years of age&#xD;
&#xD;
          -  Able to understand and sign the Informed Consent Document&#xD;
&#xD;
          -  Clinical performance status of Eastern Cooperative Oncology Group (ECOG) less than or&#xD;
             equal to 2&#xD;
&#xD;
          -  Life expectancy of greater than three months&#xD;
&#xD;
          -  Patients of both genders must be willing to practice birth control during and for four&#xD;
             months after receiving chemotherapy&#xD;
&#xD;
          -  Hematology:&#xD;
&#xD;
               -  Absolute neutrophil count greater than 1500/mm^3 without the support of&#xD;
                  Filgrastim.&#xD;
&#xD;
               -  Platelet count greater than 75,000/mm^3.&#xD;
&#xD;
               -  Hemoglobin greater than 8.0 g/dl.&#xD;
&#xD;
          -  Chemistry:&#xD;
&#xD;
               -  Serum creatinine less than or equal to 1.5 mg/dl unless the measured creatinine&#xD;
                  clearance is greater than 60 mL/min/1.73 m2&#xD;
&#xD;
               -  serum aspartate aminotransferase (AST) and alanine aminotransferase (ALT) within&#xD;
                  5 times the upper limit of normal and a total serum bilirubin of less than 3&#xD;
                  times the upper limit of normal, both of which define the upper limit of grade 2&#xD;
                  treatment related toxicities.&#xD;
&#xD;
               -  Prothrombin time (PT) within 2 seconds of the upper limit of normal (INR less&#xD;
                  than or equal to 1.8)&#xD;
&#xD;
          -  Recovered from any toxicity to grade 2 or less from all prior chemotherapy,&#xD;
             immunotherapy or radiotherapy and be at least 30 days past the date of their last&#xD;
             treatment with the exception of mitotane which may be continued.&#xD;
&#xD;
          -  Able to understand their disease and the exploratory nature of combining surgery and&#xD;
             HIPEC for this histology.&#xD;
&#xD;
        EXCLUSION CRITERIA&#xD;
&#xD;
          -  Concomitant medical problems that would place the patient at unacceptable risk for a&#xD;
             major surgical procedure.&#xD;
&#xD;
          -  History of congestive heart failure and/or an left ventricular ejection fraction&#xD;
             (LVEF) less than 40%&#xD;
&#xD;
        Note: Patients at increased risk for coronary artery disease or cardiac dysfunction (e.g.,&#xD;
        greater than 65yo, diabetes, history of hypertension, elevated LDL, first degree relative&#xD;
        with coronary artery disease) will undergo full cardiac evaluation and will not be eligible&#xD;
        if they demonstrate significant irreversible ischemia on stress thallium or an ejection&#xD;
        fraction less than 40%.&#xD;
&#xD;
        - Significant chronic obstructive pulmonary disease (COPD) or other chronic pulmonary&#xD;
        restrictive disease with pulmonary function test (PFT) indicating an forced expiratory&#xD;
        volume at one second (FEV1) less than 50% or a diffusing capacity of lung for carbon&#xD;
        monoxide (DLCO) less than 40% predicted for age.&#xD;
&#xD;
        Note: Patients who have shortness of breath with minimal exertion or who are at risk for&#xD;
        pulmonary disease (e.g., chronic smokers) will undergo pulmonary function testing and will&#xD;
        not be eligible if their FEV1 is less than 50% of expected.&#xD;
&#xD;
          -  Grade 2 or greater neuropathy&#xD;
&#xD;
          -  Women of child-bearing potential who are pregnant or breastfeeding because of the&#xD;
             potentially dangerous effects of the chemotherapy on the fetus or infant.&#xD;
&#xD;
          -  Brain metastases or a history of brain metastases&#xD;
&#xD;
          -  Childs B or C cirrhosis&#xD;
&#xD;
          -  Evidence of severe portal hypertension by history, endoscopy, or radiologic studies&#xD;
&#xD;
        Note: Any diagnosis of portal hypertension or clinical stigmata of such including but not&#xD;
        limited to gastric or esophageal varices, umbilical vein varices or telangiectasias.&#xD;
&#xD;
          -  Weight less than 30 kg&#xD;
&#xD;
          -  Active systemic infections, coagulation disorders or other major medical illnesses of&#xD;
             the cardiovascular, respiratory or immune system, myocardial infarction, cardiac&#xD;
             arrhythmias, obstructive or restrictive pulmonary disease&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Kluger, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Columbia University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Michael Kluger, MD</last_name>
    <phone>212-305-6514</phone>
    <email>mk2462@cumc.columbia.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Vilma L Rosario</last_name>
    <phone>212-305-6033</phone>
    <email>vr2222@cumc.columbia.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032-3729</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Kluger, MD</last_name>
      <phone>212-305-6514</phone>
      <email>mk2462@cumc.columbia.edu</email>
    </contact>
    <contact_backup>
      <last_name>Vilma Rosario</last_name>
      <phone>212-305-6033</phone>
      <email>vr2222@cumc.columbia.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Michael Kluger, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Antonio T Fojo, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>April 2, 2017</study_first_submitted>
  <study_first_submitted_qc>April 24, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 25, 2017</study_first_posted>
  <last_update_submitted>January 27, 2021</last_update_submitted>
  <last_update_submitted_qc>January 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Columbia University</investigator_affiliation>
    <investigator_full_name>Michael Kluger</investigator_full_name>
    <investigator_title>Assistant Professor of Surgery</investigator_title>
  </responsible_party>
  <keyword>Cisplatin</keyword>
  <keyword>Heated Cisplatin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Peritoneal Neoplasms</mesh_term>
    <mesh_term>Adrenocortical Carcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sodium thiosulfate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

